You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Toronto Central Regional Cancer Program

The Toronto Central Regional Cancer Program oversees the quality and delivery of cancer services for the residents of Toronto Central.

Service Partners 

Odette Cancer Centre

Opened in 1982 on the campus of Sunnybrook Hospital — now known as the Sunnybrook Health Sciences Centre — the Odette Cancer Centre sees 10,000 new patients per year. It boasts expert multidisciplinary health teams as well as state-of-the-art facilities that include 13 radiation treatment machines a new, state-of-the art Gamma Knife Icon, and an MR-Linac that we will installed in 2017.

In addition to providing the full spectrum of patient care, including preventive oncology, surgical oncology, chemotherapy, radiation oncology, medical imaging, psychosocial and palliative care, the Odette Cancer Centre is also intensively engaged in research, education and community outreach. The centre offers specialized clinics, including a clinic for women with locally advanced breast cancer, a program for young women with breast cancer and a clinic for women with gynecological malignancies who have sexual concerns. 

Odette Cancer Centre offers specialty residency training and fellowship programs in partnership with the University of Toronto.

 

Princess Margaret Cancer Centre

Opened in May 1958, the Princess Margaret Cancer Centre is an internationally recognized leader in the fight against cancer. Clinical and research staff include experts in oncology, with specialties that include surgical oncology, bone marrow transplantation, chemotherapy, hematology, radiation treatment, medical imaging and psychosocial oncology. 

The hospital underwent a $15-million renovation completed in 1998. This renovation created treatment centres focusing on specific cancers including breast, prostate, brain tumours, and head and neck cancers. The hospital’s 750,000-square foot facility houses 202 patient beds, 350 ambulatory clinics, 397,000-square feet of research space, and 18 radiation treatment machines in special underground concrete bunkers. 

The cancer centre, part of the University Health Network, celebrated its 50th anniversary in 2008. During these 5 decades, the hospital treated more than 350,000 cancer patients. In 2014, the Princess Margaret Cancer Centre treated 17,460 new patients and provided diagnosis, treatment and follow-up care at 370,000 clinic visits.

Over the past 20 years, there has been steady growth in the oncology programs at Princess Margaret Cancer Centre.

To continue to meet the demand for services and to improve the patient experience, the cancer centre began a multi-year renovation in mid-2017.

Partner Hospitals 

Vice-Presidents 

Cancer Care Ontario Regional Vice-Presidents, Toronto Central Regional Cancer Program

Dr. Calvin H.L. Law, Regional Vice-President for Toronto Central Regional Cancer Program”

Dr. Calvin H.L. Law

Dr. Calvin Law is the Chief, Odette Cancer Centre, and Regional Vice-President, Cancer Care Ontario. He is a cancer surgeon specializing in hepatobiliary, pancreatic and
gastrointestinal surgical oncologist. He currently holds several
leadership positions including:

  • Cancer Care Ontario Head and Regional Lead of Surgical Oncology for Toronto Central North 
  • Chair for Gastrointestinal Oncology Site Group at Edmond Odette Cancer Centre, Sunnybrook Health Sciences Centre
  • Hanna Family Research Chair in Surgical Oncology at the University of Toronto
  • Adjunct Scientist for the Institute of Clinical Evaluative Sciences

He is also an associate professor at the University of Toronto in surgery and is cross-appointed to the department of Health Policy, Management and Evaluation. 

Dr. Law completed his medical school training at the University of Toronto, and went on to Cambridge, Massachusetts to complete his masters of public health at Harvard University. Dr. Law  has served many roles including:  

  • national chair for several Canadian cancer groups
  • co-founder and director of the Susan Leslie Clinic for Neuroendocrine Tumours
  • member of the Program in Evidence-Based Care for Gastrointestinal Oncology at Cancer Care Ontario
  • examiner for the Royal College of Physicians and Surgeons of Canada

Dr. Keith Stewart

Dr. Keith Stewart

Dr. Keith Stewart is the Vice-President, Cancer, and Director of the Princess Margaret Cancer Program, University Health Network, and Regional Vice-President, Toronto Central South Regional Cancer Program, Ontario Health.

Previously, Dr. Stewart was the Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine, and recognized as the Vasek and Anna Maria Polak Professor of Cancer Research.

Dr. Stewart received his medical degree at Aberdeen University Medical School, and trained in internal medicine and hematology in Glasgow, Kingston, Toronto and Boston. He was active staff at the Toronto General and Princess Margaret hospitals from 1992 to 2005, and held the J. Gerald Scott/David G. Whitmore Chair in Hematology and Gene Therapy at the University of Toronto. In 2002, he completed a Master in Business Administration at the Ivey Business School, University of Western Ontario.

Dr. Stewart has served in several leadership roles across both research and clinical practice in Toronto and at the Mayo Clinic, including as director of Research at Toronto General Hospital, and founding director of the McLaughlin Centre for Molecular Medicine at the University of Toronto. At the Mayo Clinic, he was the dean for Research in Arizona, and a member of the Arizona Executive Operations Team and Clinical Practice committee. He has served on multiple boards for both non-profit and commercial organizations. Currently, he is a non-executive board member with Genomics England, a member of the advisory boards of Helix, Veritas Genetics, and Tempus, and a member of the Multiple Myeloma Research Foundation Investment Committee.